Ellen Scherl
Expertise in
17
conditions

Dr. Ellen Scherl

Gastroenterology
Jill Roberts Center For Inflammatory Bowel Disease
1283 York Ave # 9, 
New York, NY 
Accepting New Patients
Offers Telehealth
Expertise in
17
conditions
Jill Roberts Center For Inflammatory Bowel Disease
1283 York Ave # 9, 
New York, NY 

Overview

Ellen Scherl is a Gastroenterologist in New York, New York. Dr. Scherl is highly rated in 17 conditions, according to our data. Her top areas of expertise are Crohn's Disease, Ulcerative Colitis, Viral Gastroenteritis, Endoscopy, and Colonoscopy. Dr. Scherl is currently accepting new patients.

Her clinical research consists of co-authoring 103 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Gastroenterology

Licenses

Internal Medicine in NY

Hospital Affiliations

New York-Presbyterian Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
MVP Health
  • EPO
  • PPO
Nippon Life
  • INSURANCE PLAN
Northwell Health
  • INSURANCE PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 22 Less Insurance Carriers -

Locations

Jill Roberts Center for Inflammatory Bowel Disease
1283 York Ave # 9, New York, NY 10065

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
Multi-Center African-American Inflammatory Bowel Disease Study (MAAIS)
Multi-Center African-American Inflammatory Bowel Disease Study (MAAIS)
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2026
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Randomized, Placebo-controlled Clinical Trial Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Subsequent Dietary Fiber in Patients With Moderate Ulcerative Colitis
A Randomized, Placebo-controlled Clinical Trial Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Subsequent Dietary Fiber in Patients With Moderate Ulcerative Colitis
Enrollment Status: Completed
Publish Date: January 03, 2025
Intervention Type: Drug, Dietary supplement
Study Drug: Fecal Microbiota Transplantation
Study Phase: Phase 2
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Other
Study Drug: Cx601
Study Phase: Phase 3
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
Efficacy and Safety of ALTB-168 in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis: a 26-week, Open-label, Multi-center, Phase II Proof of Principle Trial
Efficacy and Safety of ALTB-168 in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis: a 26-week, Open-label, Multi-center, Phase II Proof of Principle Trial
Enrollment Status: Terminated
Publish Date: January 05, 2024
Intervention Type: Biological
Study Phase: Phase 2
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
Open Label, Randomized, Multicenter, Comparative Effectiveness Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission in Patients With Crohn's Disease
Open Label, Randomized, Multicenter, Comparative Effectiveness Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission in Patients With Crohn's Disease
Enrollment Status: Completed
Publish Date: July 21, 2021
Intervention Type: Other
Study Phase: Not Applicable
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
Enrollment Status: Terminated
Publish Date: April 26, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 11 Less Clinical Trials

103 Total Publications

Spatial transcriptomics reveals unique inflammatory signatures across all anatomic locations in postoperative Crohn's disease.
Spatial transcriptomics reveals unique inflammatory signatures across all anatomic locations in postoperative Crohn's disease.
Journal: Journal of Crohn's & colitis
Published: October 15, 2025
Similar Doctors
Expertise in
18
conditions
Dr. David Katzka
Gastroenterology
Expertise in
18
conditions
Dr. David Katzka
Gastroenterology

ColumbiaDoctors - Midtown

51 W 51st St Ste 360, 
New York, NY 
 (1.7 miles away)
646-661-2756
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Katzka is a Gastroenterologist in New York, New York. Dr. Katzka is highly rated in 18 conditions, according to our data. His top areas of expertise are Esophagitis, Eosinophilic Esophagitis, Barrett Esophagus, Endoscopy, and Gastrectomy.

Bo Shen
Expertise in
35
conditions
Dr. Bo Shen
Gastroenterology
Expertise in
35
conditions
Dr. Bo Shen
Gastroenterology

CUIMC/Herbert Irving Pavilion

161 Fort Washington Avenue, Floor 8, 
New York, NY 
 (5.3 miles away)
212-305-9664
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Bo Shen, MD, is one of the world’s pre-eminent leaders in interventional inflammatory bowel disease (IBD) and pouch-related disorders due to his specialized expertise and experience treating a wide range of these conditions. Dr. Shen is the director of the IBD Center at Columbia and co-director of Columbia’s Global Center for Integrated Colorectal Surgery and IBD Interventional Endoscopy. He is also the Vice Chair for Innovation in Medicine and Surgery and a Professor of Medicine (in Surgery) and Edelman-Jarislowsky Professor in Surgical Sciences.In addition to pouchitis and pouch diseases, Dr. Shen specializes in critical diagnostic evaluation, and medical and endoscopic management of IBD, GI endoscopy and imaging technology. Dr. Shen is known as a pioneer in interventional endoscopic therapy for IBD and ileal pouch disorders - this includes postponing or eliminating the need for surgery in some cases.Dr. Shen comes to Columbia/NewYork-Presbyterian from the Cleveland Clinic, where he served as medical director for the Center of Inflammatory Bowel Diseases and the Ed and Joey Story Endowed Chair, Digestive Disease and Surgery Institute. While there, Dr. Shen established a subspecialty Pouchitis Clinic and Interventional IBD Unite - the first and largest of its kind in the United States. He also created an IBD Board, modeled after oncology tumor boards, to help manage the most challenging cases with multiple specialists.A prolific researcher in the field with more than 600 peer-reviewed articles, Dr. Shen is funded by a number of government and philanthropic organizations, including the NIH, the American Gastroenterological Association, American College of Gastroenterology, the Broad Foundation, and the Crohn’s and Colitis Foundation of America. Dr. Shen is highly rated in 35 conditions, according to our data. His top areas of expertise are Crohn's Disease, Viral Gastroenteritis, Colitis, Ileostomy, and Endoscopy.

Expertise in
31
conditions
Dr. Thomas Schiano
Gastroenterology
Expertise in
31
conditions
Dr. Thomas Schiano
Gastroenterology

Recanati Miller Transplantation Institute

5 E 98th St Fl 12, 
New York, NY 
 (2.0 miles away)
212-257-0031
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Thomas Schiano is a Gastroenterologist in New York, New York. Dr. Schiano is highly rated in 31 conditions, according to our data. His top areas of expertise are Hepatitis, Hepatitis C, Autoimmune Hepatitis, Liver Transplant, and Splenectomy.

Frequently Asked Questions about Dr. Ellen Scherl

How do I make an appointment with Dr. Ellen Scherl?

You can book an appointment with Dr. Ellen Scherl by calling their office at 347-719-4936. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ellen Scherl a top-rated expert for Crohn's Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ellen Scherl is classified as an Elite expert for Crohn's Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ellen Scherl specialize in?

While Dr. Ellen Scherl is a Gastroenterology, they have specific expertise in Crohn's Disease, Ulcerative Colitis, and Viral Gastroenteritis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Ellen Scherl participate in research or clinical trials?

Yes. Dr. Ellen Scherl has published 103 articles and abstracts on conditions like Crohn's Disease. You can view a list of Dr. Ellen Scherl's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ellen Scherl accept my insurance?

Dr. Ellen Scherl accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 347-719-4936 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Scherl's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile